NCT04843046View on ClinicalTrials.gov

Pioglitazone as an Adjunct to Cognitive-Behavioral Therapy for Cocaine Relapse Prevention

PHASE2RecruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

August 23, 2021

Primary Completion Date

February 28, 2026

Study Completion Date

February 28, 2026

Conditions
Cocaine Use Disorder
Interventions
BEHAVIORAL

Cognitive Behavioral Therapy (CBT)

All participants will receive evidence-based individual Cognitive Behavioral Therapy (CBT) shown to be an effective intervention for maintaining abstinence following detoxification. Trained masters-level licensed professional counselors will deliver CBT.

DRUG

Pioglitazone

Pioglitazone capsules will start at 30 mg (Detox days 3 and 4) and increase to fixed dose of 45 mg for study weeks 1-12 and will also contain riboflavin.

DRUG

Placebo

Placebo capsules will be filled with corn starch and riboflavin.

Trial Locations (1)

77054

RECRUITING

UTHealth Center for Neurobehavioral Research on Addiction, Houston

All Listed Sponsors
collaborator

National Institute on Drug Abuse (NIDA)

NIH

lead

The University of Texas Health Science Center, Houston

OTHER